Francisco Cano, MD
Allergy & Immunology · Greenville, PANPI 1881660249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 461 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,540, 2.4 times the $1,070 reported in 2019.
Across 461 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$1K
- CSL Behring$878
- Regeneron Healthcare Solutions, Inc.$840
- Amgen$651
- plus $4K from 23 others
What the payments were for
- Consulting fees$140%
- Food & beverage$10,70199%
- Education$741%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $1,959 |
| GSK | 82 | $1,243 |
| Sanofi | 39 | $1,124 |
| CSL Behring | 30 | $878 |
| Regeneron Healthcare Solutions, Inc. | 38 | $840 |
| Amgen | 20 | $651 |
| Genentech USA, Inc. | 20 | $642 |
| Novartis | 29 | $532 |
| Grifols USA, LLC | 26 | $500 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $427 |
| Pfizer | 18 | $358 |
| Biocryst US Sales Co., LLC | 10 | $316 |
| Kaleo, Inc. | 17 | $289 |
| Optinose US, Inc. | 13 | $209 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 7 | $120 |
| Pharming Healthcare, Inc. | 1 | $109 |
| Ionis Pharmaceuticals, Inc. | 3 | $75 |
| Sanofi-aventis U.S. LLC | 1 | $64 |
| Alk-abello, Inc | 3 | $63 |
| Aimmune Therapeutics, Inc. | 3 | $60 |
| Boehringer Ingelheim | 3 | $47 |
| Merck | 2 | $37 |
| Cycle Pharmaceuticals Inc | 2 | $32 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Organon | 1 | $21 |
| Shire North American Group Inc | 1 | $18 |
| Circassia Inc. | 1 | $14 |
| ADMA Biomanufacturing LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,788 in reported general payments places this provider in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 17 | $730,599 |
| Dupixent PenDupilumab | 47 | $226,482 |
| NucalaMepolizumab | 18 | $69,017 |
| TezspireTezepelumab-Ekko | 12 | $50,925 |
| Dupixent SyringeDupilumab | 14 | $50,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $37,724 |
| XolairOmalizumab | 13 | $35,510 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $21,848 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $8,059 |
| Epinephrine | 24 | $4,717 |
| Arnuity ElliptaFluticasone Furoate | 21 | $4,308 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $4,177 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $3,213 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,652 |
| Ventolin HfaAlbuterol Sulfate | 11 | $1,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda | $878 | $730,59917 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,243 | $132,897137 claims |
| AstraZenecaTezspire, Symbicort | $1,959 | $58,98441 claims |
| Hikma Pharmaceuticals USAEpinephrine | $22 | $4,71724 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $120 | $4,17717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Greenville
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
- Michael PremattaHavertown$168K
- Donald HarperMechanicsburg$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.